Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety.

By J. Hirsh, T. Warkentin, S. Shaughnessy, Sonia S Anand, J. Halperin, R. Raschke, C. Granger, E. Ohman, J. Dalen. Chest, 2001

1,534 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Heparin prevents antiphospholipid antibody–induced fetal loss by inhibiting complement activation (2004, background): “Indeed, subanticoagulant doses of heparin have therapeutic benefits in other conditions in which complement activation is thought to have a role, including reperfusion injury and coronary artery diseas”
ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Commit (2006, positive): “These include a longer half-life, more predictable bioavailability (greater than 90% after subcutaneous injection), predictable clearance (enabling once- or twicedaily subcutaneous administration), and a predictable antithrombotic response based on body weight, which permits fixed-dose treatment wit”